Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies.

By P. Piedra, A. Jewell, S. Cron, R. Atmar, W. Glezen. 2003

220 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus (2019, background): “, 2017), high levels of which correlate with a lower risk of infection (Falsey andWalsh, 1998; Glezen et al., 1986; Piedra et al., 2003).”
Nonviral delivery of self-amplifying RNA vaccines (2012, background): “The neutralization titers elicited by LNP/RNA are above the titer of 380 that correlates with protection in cotton rats (30) and similar to passively acquired serum neutralizing titers that correlate with protection of human infants from severe RSV disease (31, 32).”
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays (2020, background): “While studies of immunity to SARS-CoV-2 are limited, for many other viruses neutralizing antibodies are more strongly correlated with protection against re-infection or disease than antibodies that bind but do not neutralize [7–10,13–15].”
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers (2011, background): “2B), well above the 1:380 that correlates with protection in cotton rats (19) and similar passively acquired serum neutralizing titers that correlate with protection of human infants from severe RSV disease (20, 21).”